Medicrea Releases Annual Sales for 2016

January 12, 2017

LYON, France & NEW YORK–(BUSINESS WIRE)–The MEDICREA Group (Alternext Paris: FR0004178572 – ALMED), worldwide leader pioneering the development and manufacture of personalized analytical services and implant solutions for the treatment of complex spinal conditions, announces its 2016 annual sales.

€ millions 2015 2016 Δ

Year to date September 2016

Advertisement

20.9

21.6

+3%

4th Quarter

6.9

7.8

+13%

TOTAL 27.8 29.4 +6%

Variations in foreign currency rates had no significant impact on 2016 annual sales.

Group Sales reached a total of €29.4 million in 2016, generating a 6% growth compared to the previous year. 4th quarter sales increased 13% compared to the same period of 2015, in line with the accelerated adoption of Medicrea’s patient-specific UNiD™ technology, notably in the United States where for the entire year the number of surgeries performed with personalized rods implants have increased by 106% compared to 2015.

The 1,000th UNiD™ Rod milestone was achieved in November (almost 1,100 surgeries performed by the end of the year) closely tracking the launch of the company’s Lifetime Warranty on UNiD™ Rod constructs.

Next publication: 2016 annual results published March 29, 2017, after market.

About MEDICREA (www.medicrea.com)

MEDICREA specializes in bringing pre-operative digital planning and pre and post-operative analytical services to the world of complex spine. Through the lens of predictive medicine, MEDICREA leads the design, integrated manufacture, and distribution of 30+ FDA approved implant technologies, utilized in over 100k spinal surgeries to date. Operating in a $10 billion marketplace, MEDICREA is an SME with 160 employees worldwide, which includes 55 at its USA Corp. subsidiary in NYC. The Company has an ultra-modern manufacturing facility in Lyon, France housing the development and production of 3D-printed titanium patient-specific implants.

By leveraging its proprietary software analysis tools with big data and deep learning technologies supported by an expansive collection of clinical and scientific data, MEDICREA is well-placed to streamline the efficiency of spinal care, reducing procedural complications and limiting time spent in the O.R.

For further information, please visit: medicrea.com.

Connect with MEDICREA:
FACEBOOK | INSTAGRAM | TWITTER | WEBSITE | YOUTUBE

MEDICREA is listed on ALTERNEXT
Paris ISIN: FR 0004178572 –
Ticker: ALMED

Contacts

MEDICREA
Denys Sournac
Founder, Chairman and CEO
dsournac@medicrea.com
or
Fabrice Kilfiger
Chief Financial Officer
+33 (0)4 72 01 87 87
fkilfiger@medicrea.com

Add a comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Keep Up to Date with the Most Important News

By pressing the Subscribe button, you confirm that you have read and are agreeing to our Privacy Policy and Terms of Use
Advertisement